Exclusive Summary

• Targeting a vast population of over 550 million asthma and COPD patients globally, nebulized inhalation therapy is a rigid and essential standard of care for pediatric, elderly, and critically ill patients.
• Although originator patents have expired, the high manufacturing barriers of sterile suspensions (particle size control & BFS technology) maintain a favorable, uncrowded competitive landscape for high-quality generics.
• Recognized as a first-line cornerstone medication by authoritative GINA and GOLD guidelines, the 0.5mg/2ml specification perfectly aligns with standard clinical nebulization dosages.
• Supported by China's robust integrated supply chain, the product matches the originator's quality while offering substantial cost-effectiveness, ensuring highly attractive profit margins for overseas distributors.